Sort   by:  
 Page size 
ProteomicsMass spectrometric ITEM-ONE analysis confirms and refines an assembled affimer binding site on the HER-2 targeting therapeutic antibody Pertuzumab
The Pertuzumab-binding affimer 00557_709097 was incubated either with peptides from tryptically digested Pertuzumab or with selected synthesized peptides. Affimer-peptide complexes were subjected to nano electrospray mass spectrometric ITEM analyses in order to identify the affimer’s epitope on Pert...
ORGANISM(S): Homo sapiens (Human) 
2024-04-09 | PXD043203 | Pride
Pertuzumab Item Affimer Offline nanoesi-ms 
TranscriptomicsDefining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer
The purpose of this study was to characterise the effects of trastuzumab and pertuzumab, either as single agents or as combination therapy on gene and protein expression in human ovarian cancer in vivo. Illumina BeadChips were used to profile the transcriptome after four days treatment of SKOV3 tumo...
ORGANISM(S): Homo sapiens 
2012-05-02 | E-GEOD-31432 | biostudies-arrayexpress
GenomicsRNA sequencing of BT474 cells treated with trastuzumab or trastuzumab + pertuzumab and BT474-derived cells resistant to trastuzumab or trastuzumab + pertuzumab
RNA sequencing of BT474 cells treated with trastuzumab or trastuzumab + pertuzumab and BT474-derived cells resistant to trastuzumab or trastuzumab + pertuzumab
PRJNA495653 | ENA
TranscriptomicsRNA sequencing of BT474 cells treated with trastuzumab or trastuzumab + pertuzumab and BT474-derived cells resistant to trastuzumab or trastuzumab + pertuzumab
We sequenced untreated BT474 cells, BT474 cells treated for three days with trastuzumab or trastuzumab + pertuzumab, as well as two BT474-derived trastuzumab-resistant pools and two BT474-derived trastuzumab + pertuzumab resistant pools. Resistant pools were generated by culturing BT474 cells in gra...
ORGANISM(S): Homo sapiens 
2020-01-26 | GSE121105 | GEO
GenomicsRNA sequencing of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model
RNA sequencing of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model
PRJNA610269 | ENA
TranscriptomicsNeoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial.
Ado-trastuzumab emtansine plus pertuzumab (T-DM1/P) and paclitaxel plus trastuzumab and pertuzumab (THP) are two of the experimental regiments evaluated in I-SPY 2, a neoadjuvant platform trial for high risk, early stage breast cancer. In pre-defined analyses we assessed 10 biomarkers at the pre-tre...
ORGANISM(S): Homo sapiens 
2021-08-24 | GSE181574 | GEO
GenomicsNeoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial.
Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2-positive breast cancer in the adaptively randomized I-SPY2 trial.
PRJNA753123 | ENA
GenomicsSerum microRNAs as biomarkers for the therapeutic response to trastuzumab/pertuzumab/taxane therapy in HER2-positive metastatic breast cancer
Serum microRNAs as biomarkers for the therapeutic response to trastuzumab/pertuzumab/taxane therapy in HER2-positive metastatic breast cancer
PRJNA505173 | ENA
TranscriptomicsRNA sequencing of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model
We report RNA sequencing data of trastuzumab plus pertuzumab-refractory tumor in a mouse xenograft model.
ORGANISM(S): Homo sapiens 
2020-03-05 | GSE146380 | GEO
GenomicsTumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy
Tumor infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: A TRYPHAENA substudy
PRJNA431776 | ENA
Sort   by:  
 Page size